LDLR and neoplasm: Targeting LDLR with the liver X receptor (LXR) agonist caused an inducible degrader of LDLR (IDOL)-mediated LDLR degradation and increased expression of the ATP-binding cassette protein A1 (ABCA1) cholesterol efflux transporter, potently promoting tumor cell death in a GBM model (Figure 4).